Bisphosphonates (BPs) are a group of anti-resorptive agents that possess high binding affinity to bone mineral. They accumulate in bone and are released during bone turnover to inhibit resorption after their internalisation by osteoclasts. This has been described as the principal mechanism of action of BPs, warranting their use in various bone depleting conditions such as osteoporosis, Paget’s disease, metastatic bone diseases (breast cancer, prostate cancer and multiple myeloma primary sites) and paediatric osteogenesis imperfecta. However, BPs are associated with a significant adverse effect that selectively occurs in jaw bones, termed Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). While the pathogenesis of BRONJ is not yet clearly understood, recent focus of research has been on their anti-angiogenic properties that could significantly contribute to the aetiopathogenic process by which the avascular necrosis of the jaw bone ensues. The focus of this project was to explore the mechanism by which the anti-angiogenic properties of BPs can lead to the occurrence of BRONJ lesions and subsequently formulate a localised approach for prevention of this painful and debilitating condition.